Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00624286
- Testing
- Indacaterol 150 μg
- Where
- 120 sites in United States, Belgium and 1 more
- Volunteers
- 416 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the efficacy and safety of two doses of indacaterol in adults aged 40 or over with chronic obstructive pulmonary disease (COPD) in China and in two other countries.
- Trial name
- NCT00792805
- Testing
- Indacaterol 150 µg, Indacaterol 300 μg
- Where
- 15 sites in Australia, China and 1 more
- Volunteers
- 563 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Bronchitis
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
- Trial name
- NCT00254566
- Testing
- Moxifloxacin, Azithromycin SR
- Where
- 34 sites in China, Malaysia and 4 more
- Volunteers
- 398 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease COPD
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
- Trial name
- NCT02238483
- Testing
- AZD7624 1.0 mg
- Where
- 41 sites in United States, Argentina and 4 more
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema
- Trial name
- NCT00680056
- Testing
- Formoterol plus Tiotropium
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Federal University of São Paulo
Bronchiolitis Obliterans
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Approximately 10,000 allogeneic hematopoietic stem cell transplants (HSCT) are performed annually in the US for various indications.
- Trial name
- NCT01163786
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113373 (NCT01313650)
- Testing
- 62.5/25mcg, 62.5mcg, 25mcg
- Where
- 165 sites in United States, Bulgaria and 11 more
- Volunteers
- 1,538 people
- Sponsor
- GlaxoSmithKline
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
COPD, Emphysema
Efficacy of Losartan in Preventing Progression of COPD
Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or…
- Conditions
- COPD, Emphysema, Chronic Bronchitis, Smoking
- Trial name
- NCT00720226
- Testing
- Losartan
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Johns Hopkins University
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
The main purpose of the study is to assess the burden of illness for, COPD using both patient-reported symptom burden and claims-based economic burden, among the subjects treated with single-inhaler dual therapy treatments…
- Trial name
- NCT03543176
- Testing
- UMEC/VI, FLUT/SAL, CAT
- Where
- United States
- Volunteers
- 789 people
- Sponsor
- GlaxoSmithKline
Anxiety
Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation
The purpose of this study is to test whether patients who are receiving mechanical ventilation in the ICU who listened to preferred, relaxing music whenever they desire for as long as they desire will have less anxiety, receive…
- Trial name
- NCT00440700
- Testing
- Anxiety Self-Management, Patient preferred relaxing music, Control 1: Noise-cancelling headphones, Control 2: Standard of Care
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- University of Minnesota
Pulmonary Disease, Chronic Obstructive
Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants
TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA)…
- Trial name
- TETRIS (NCT04657211)
- Testing
- Prospective observational cohort study
- Where
- Germany
- Volunteers
- 1,212 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease…
- Trial name
- NCT02164539
- Testing
- FF, UMEC, VI
- Where
- 67 sites in United States, Argentina and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
COPD
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
- Trial name
- GLAD (NCT00929708)
- Testing
- AZD3199, formoterol
- Where
- 38 sites in Bulgaria, Canada and 3 more
- Volunteers
- 329 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Chronic Obstructive Pulmonary Disease (COPD)
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indacaterol in Japan.
- Trial name
- NCT00876694
- Testing
- Indacaterol 300 µg, Salmeterol 50 µg
- Where
- 37 sites in Japan
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
This is a randomized, open-label, parallel group, multicenter, outpatient study in COPD subjects who are discharged from the hospital due to a COPD exacerbation.
- Trial name
- NCT02275481
- Testing
- Arformoterol tartrate inhalation solution, Tiotropium
- Where
- 28 sites in United States
- Volunteers
- 66 people
- Sponsor
- Sumitomo Pharma America, Inc.
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS).
- Conditions
- Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
- Trial name
- NCT01650545
- Testing
- Liposomal aerosol cyclosporine, standard immune suppression, oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Chronic Obstructive Pulmonary Disease
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to…
- Trial name
- GLOW4 (NCT01119937)
- Testing
- NVA237, Tiotropium
- Where
- 40 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.